1. A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study.
- Author
-
Joly, Florence, Fabbro, Michel, Follana, Philippe, Lequesne, Justine, Medioni, Jacques, Lesoin, Anne, Frenel, Jean-Sébastien, Abadie-Lacourtoisie, Sophie, Floquet, Anne, Gladieff, Laurence, You, Benoît, Gavoille, Céline, Kalbacher, Elsa, Briand, Mélanie, Brachet, Pierre-Emmanuel, Giffard, Florence, Weiswald, Louis-Bastien, Just, Pierre-Alexandre, Blanc-Fournier, Cécile, and Leconte, Alexandra
- Subjects
- *
OVARIAN cancer , *OVARIAN epithelial cancer , *BCL-2 proteins , *PROGRESSION-free survival , *TUMOR proteins , *DISEASE relapse - Abstract
There are limited treatment options for ovarian cancer patients with early relapse after platinum chemotherapy. In preclinical studies, we previously demonstrated the promising activity of ABT-737, a Bcl-2/Bcl-x L anti-apoptotic protein inhibitor, in chemo-resistant ovarian cancer cells and tumors, suggesting its potential activity in platinum-resistant patients. We conducted a prospective multicenter single-arm phase II study to assess the efficacy of Navitoclax (orally available ABT-737 analogue) monotherapy in 46 heavily pretreated (2–12 lines, median = 4) patients with high-grade serous platinum-resistant ovarian tumors. Navitoclax was administered at the daily dose of 150 mg during a lead-in period (7–14 days) and then increased to 250 mg daily in the absence of dose-limiting thrombocytopenia (
- Published
- 2022
- Full Text
- View/download PDF